Effects of Long-Term Administration of Busulfan

M, Feingold; Koss, Leopold G.

doi:10.1001/archinte.1969.00300170068013

Cited by 45 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytological changes in the pancreatic acinar cells and islet cells have also been described (Feingold and Koss, 1969). However liver changes have been much less striking than in our case.…”

Section: Commentsupporting

confidence: 69%

Extreme dysplasla in renal epithelium of a young woman dying from hepatocarcinoma

Burry

1974

The Journal of Pathology

View full text Add to dashboard Cite

“…Cytological changes in the pancreatic acinar cells and islet cells have also been described (Feingold and Koss, 1969). However liver changes have been much less striking than in our case.…”

Section: Commentsupporting

confidence: 69%

Extreme dysplasla in renal epithelium of a young woman dying from hepatocarcinoma

Burry

1974

The Journal of Pathology

View full text Add to dashboard Cite

“…However, other reported side effects of BU therapy are interstitial pulmonary fibrosis (busulphan lung), hyperpigmentation of the skin, ovarian suppression and amenorrhea, and cataract formation (Leake et al 1963;Burns et al 1970;Oakhill et al 1981;Reynolds 1993;Dollery 1999). BU is potentially teratogenic and carcinogenic (Feingold and Koss 1969;IARC 1987;Reynolds 1993;Dollery 1999).…”

Section: Discussionmentioning

confidence: 99%

Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration

et al. 2010

View full text Add to dashboard Cite

Many anticancer drugs are myelotoxic and cause bone marrow depression; however, generally, the marrow/blood returns to normal after treatment. Nevertheless, after the administration of some anti-neoplastic agents (e.g. busulphan, BU) under conditions as yet undefined, the marrow may begin a return towards normal, but normality may not be achieved, and late-stage/residual marrow injury may be evident. The present studies were conducted to develop a short-term mouse model (a 'screen') to identify late-stage/residual marrow injury using a brief regimen of drug administration. Female BALB/c mice were treated with BU, doxorubicin (DOX), cisplatin (CISPLAT) or cyclophosphamide (CYCLOPHOS) on days 1, 3 and 5. In 'preliminary studies', a maximum tolerated dose (MTD) for each drug was determined for use in 'main studies'. In main studies, mice were treated with vehicle (control), low and high (the MTD) dose levels of each agent. Necropsies were performed, and blood parameters and femoral/humeral nucleated marrow cell counts (FNCC/HNCC) were assessed on six occasions (from days 1 to 60/61 post-dosing). Late-stage/residual changes were apparent in BU-treated mice at day 61 post-dosing: RBC, Hb and haematocrit were reduced, mean cell volume/mean cell haemoglobin were increased and platelet and FNCC counts were decreased. Mice given DOX, CISPLAT and CYCLOPHOS, in general, showed no clear late-stage/residual effects (day 60/61). It was concluded that a brief regimen of drug administration, at an MTD, with assessment at day 60/61 post-dosing was a suitable short-term method/screen in the mouse for detecting late-stage/residual marrow injury for BU, a drug shown to exhibit these effects in man.

show abstract

“…It is generally accepted that cytostatic agents, particularly the alkylating agents, are potential carcinogens (Bylandj 1964). Feingold & Koss (1969) reported a patient who developed carcinoma of the vulva after 6 years of busulphan therapy for chronic myeloid leukaemia. The possibility of the carcinoma being secondary to busulphan treatment was discussed.…”

Section: Carcinogenesismentioning

confidence: 99%